Pipeline Watch: Phase III Starts With Plinabulin, Rova-T And Relugolix
Executive Summary
Pipeline Watch is Scrip's weekly update on the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
You may also be interested in...
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Denmark's IO Vaccine Biotech Attracts Investor Interest
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
COVID-19 Could Change Attitudes To Flu, Bolster Xofluza
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.
Need a specific report? 1000+ reports available
Buy Reports